Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer

Franziska Haderk, Yu‐Ting Chou, Lauren Čech, Celia Fernández-Méndez, Johnny Yu, Victor Olivas, Ismail M. Meraz, Dora Barbosa Rabago, D. Lucas Kerr, Carlos F. Gómez, David V. Allegakoen, Juan Guan, Khyati N. Shah, Kari A. Herrington, Oghenekevwe M. Gbenedio, Shigeki Nanjo, Mourad Majidi, Whitney Tamaki, Yashar K. Pourmoghadam, Julia Rotow, Caroline E. McCoach, Jonathan W. Riess, J. Silvio Gutkind, Tracy Tang, Leonard Post, Bo Huang, Pilar Santisteban, Hani Goodarzi, Sourav Bandyopadhyay, Calvin J. Kuo, Jeroen P. Roose, Wei Wu, Collin M. Blakely, Jack A. Roth, Trever G. BivonaNature Communications 2024 · DOI

Abstract

Targeted therapy is effective in many tumor types including lung cancer, the leading cause of cancer mortality. Paradigm defining examples are targeted therapies directed against non-small cell lung cancer (NSCLC) subtypes with oncogenic alterations in EGFR, ALK and KRAS. The success of targeted therapy is limited by drug-tolerant persister cells (DTPs) which withstand and adapt to treatment and comprise the residual disease state that is typical during treatment with clinical targeted therapies. Here, we integrate studies in patient-derived and immunocompetent lung cancer models and clinical specimens obtained from patients on targeted therapy to uncover a focal adhesion kinase (FAK)-YAP signaling axis that promotes residual disease during oncogenic EGFR-, ALK-, and KRAS-targeted therapies. FAK-YAP signaling inhibition combined with the primary targeted therapy suppressed residual drug-tolerant cells and enhanced tumor responses. This study unveils a FAK-YAP signaling module that promotes residual disease in lung cancer and mechanism-based therapeutic strategies to improve tumor response.

Introduction: The Challenge of Residual Disease

In the era of precision medicine, targeted therapies such as Osimertinib for EGFR-mutant or Alectinib for ALK-fusion non-small cell lung cancers (NSCLC) have revolutionized the treatment landscape. Despite high initial response rates, these therapies are rarely curative. Most patients eventually experience disease progression originating from a state of "minimal residual disease." This state is characterized by the survival of a subpopulation of cells known as drug-tolerant persisters (DTPs).

DTPs are distinct from classically resistant cells; they have not necessarily acquired new genetic mutations but have instead adapted to survive in a slow-cycling, non-proliferative state under constant drug pressure. These cells serve as a reservoir for the eventual emergence of fully resistant, proliferative tumors. Understanding the molecular mechanisms that sustain DTPs is critical for developing therapies that can eliminate residual disease and prevent clinical relapse.

Characterization of drug-tolerant persister (DTP) cells and their evolution under targeted therapy.

Methodology

The researchers employed a multi-disciplinary approach to map the evolution and survival mechanisms of DTPs. Key methodologies included:

  • Transcriptional Trajectory Mapping: Longitudinal single-cell RNA sequencing (scRNA-seq) and genetic barcoding were used to track how individual cancer cell clones adapt over time under drug pressure in EGFR-mutant (PC9, H1975) and ALK-fusion (H3122) models.
  • Mechanistic Dissection: Proximity Ligation Assays (PLA) and nuclear-cytoplasmic fractionation were utilized to monitor the activity and localization of YAP, a key transcriptional co-activator.
  • Pharmacological Screening: The NIH LINCS L1000 database was queried to identify compounds capable of reversing the gene expression signatures associated with residual disease.
  • Advanced In Vivo Modeling: Findings were validated in patient-derived organoids (PDOs), patient-derived xenografts (PDX), and humanized mouse models engrafted with human CD34+ stem cells to evaluate the interaction between DTPs and the immune system.

Results: The FAK-YAP Signaling Axis

YAP as a Central Survival Hub

The study identified YAP (Yes-associated protein) as a critical driver of the DTP state. Upon initiation of targeted therapy, YAP rapidly translocates to the nucleus—often within 24 hours—peaking during the establishment of the DTP state. This nuclear activity drives the expression of a survival-associated gene program, including FGFR1 and BCL-XL, which protects cells from drug-induced apoptosis.

Non-Canonical Activation via FAK

While YAP is traditionally regulated by the Hippo pathway, the authors discovered a non-canonical activation route in DTPs. Focal Adhesion Kinase (FAK), a protein that mediates cellular responses to the physical microenvironment, was found to act as the primary upstream driver of YAP activation in this context. This suggests that the physical state and environmental sensing of the cancer cell are integral to its survival during therapy.

Adaptation over Selection

Genetic barcoding experiments revealed that the DTP state is not restricted to a few pre-existing "special" clones. Instead, a wide variety of clones are capable of undergoing transcriptional reprogramming to reach the drug-tolerant state, suggesting that persister formation is a widespread adaptive response rather than a simple selection of rare resistant variants.

Immune Evasion and the Microenvironment

Beyond cell-intrinsic survival, YAP activity was found to reshape the tumor microenvironment. High YAP levels in residual disease were associated with an increase in pro-tumor "M2" macrophages and a concomitant decrease in effective T-cell infiltration, suggesting that DTPs utilize the FAK-YAP axis to hide from the immune system.

Discussion and Future Directions

The identification of the FAK-YAP signaling axis provides a clear therapeutic target for eliminating residual disease. In preclinical models, combining primary targeted therapy with FAK inhibitors (e.g., VS-4718) or YAP/TEAD inhibitors (e.g., VT-104/108) significantly reduced DTP populations and delayed tumor regrowth compared to standard single-agent therapy.

However, several challenges remain for clinical translation. While DTPs adopt an "alveolar-like" state, the full extent of their lineage plasticity and its relationship to Epithelial-Mesenchymal Transition (EMT) requires further study. Furthermore, moving these combination therapies into clinical trials will necessitate careful monitoring of potential overlapping toxicities. Despite these hurdles, co-targeting the FAK-YAP axis represents a promising strategy to turn transient responses into durable cures for lung cancer patients.

Summary updated

Abstract

Targeted therapy is effective in many tumor types including lung cancer, the leading cause of cancer mortality. Paradigm defining examples are targeted therapies directed against non-small cell lung cancer (NSCLC) subtypes with oncogenic alterations in EGFR, ALK and KRAS. The success of targeted therapy is limited by drug-tolerant persister cells (DTPs) which withstand and adapt to treatment and comprise the residual disease state that is typical during treatment with clinical targeted therapies. Here, we integrate studies in patient-derived and immunocompetent lung cancer models and clinical specimens obtained from patients on targeted therapy to uncover a focal adhesion kinase (FAK)-YAP signaling axis that promotes residual disease during oncogenic EGFR-, ALK-, and KRAS-targeted therapies. FAK-YAP signaling inhibition combined with the primary targeted therapy suppressed residual drug-tolerant cells and enhanced tumor responses. This study unveils a FAK-YAP signaling module that promotes residual disease in lung cancer and mechanism-based therapeutic strategies to improve tumor response.
BibTeX
@inproceedings{haderk2024focal,
  author = {Franziska Haderk and Yu‐Ting Chou and Lauren Čech and Celia Fernández-Méndez and Johnny Yu and Victor Olivas and Ismail M. Meraz and Dora Barbosa Rabago and D. Lucas Kerr and Carlos F. Gómez and David V. Allegakoen and Juan Guan and Khyati N. Shah and Kari A. Herrington and Oghenekevwe M. Gbenedio and Shigeki Nanjo and Mourad Majidi and Whitney Tamaki and Yashar K. Pourmoghadam and Julia Rotow and Caroline E. McCoach and Jonathan W. Riess and J. Silvio Gutkind and Tracy Tang and Leonard Post and Bo Huang and Pilar Santisteban and Hani Goodarzi and Sourav Bandyopadhyay and Calvin J. Kuo and Jeroen P. Roose and Wei Wu and Collin M. Blakely and Jack A. Roth and Trever G. Bivona},
  title = {{Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer}},
  booktitle = {Nature Communications},
  year = {2024},
  doi = {10.1038/s41467-024-47423-0},
}
Figure